<DOC>
	<DOCNO>NCT01570478</DOCNO>
	<brief_summary>The purpose present study demonstrate high efficacy Foster® NEXThaler® 100/6 extra fine ( two inhalation b.i.d . ) versus Seretide® Accuhaler® 250/50 ( one inhalation b.i.d . ) , term pulmonary function ( change baseline end treatment post-dose peripheral airway resistance ) patient asthma .</brief_summary>
	<brief_title>A Study Patients With Asthma</brief_title>
	<detailed_description>Asthma chronic inflammatory disease characterise variable airflow obstruction bronchial hyper responsiveness . Asthma affect large small airway grow body evidence small airway impairment important contributor pathogenesis clinical expression disease .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female outpatient age ≥ 18 , sign Informed Consent form prior initiation studyrelated procedure . Clinical diagnosis asthma minimum 12 month prior screen confirm chest physician accord international guideline ( GINA ) . The evidence asthma must confirm document ( last three year ) positive response reversibility test , define ΔFEV1 ≥ 12 % ≥ 200 mL baseline , within 30 minute administration 400 μg salbutamol pMDI document ( last three year ) positive response methacholine challenge test ( PC20 &lt; 8 mg/mL PD20 &lt; 1 mg ) . Baseline FEV1 &gt; 80 % predict normal value appropriate washout bronchodilator ( checked screening randomisation visit ) . Asthma Control Test score ≥ 20 &lt; 25 ( check screen randomisation visit ) . Impaired small airway function define baseline peripheral airway resistance [ R ( 5Hz ) R ( 20Hz ) ] ≥ 0.07 kPa/L/s ( checked screening randomisation visit ) . Patients previous regular treatment Seretide® Accuhaler® ( fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation , daily dose fluticasone 500 μg plus salmeterol 100 μg ) stable dose least 2 month prior inclusion . A cooperative attitude ability train proper use DPI . Main Patients diagnosis COPD accord GOLD guideline . Current smoker smoke history &gt; 10 pack/year . Patients clinical functional uncontrolled respiratory , haematological , immunologic , renal , neurologic , hepatic , endocrinal disease , condition might , judgment investigator , represent patient undue risk could compromise result interpretation study . History current evidence uncontrolled heart failure , clinically relevant coronary artery disease , recent myocardial infarction , severe hypertension , uncontrolled cardiac arrhythmia . Patients treat LABA ICS/LABA fix combination 24 hour screen visit . Severe asthma exacerbation lead intake systemic corticosteroid ( &gt; 10 day ) month screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>